• Biolinerx Ltd., of Jerusalem, said it signed an out-licensing agreement with Jiagsu chia-tai Tianqing Pharmaceutical Co. Ltd. (CCTQ), of Jiangsu, China, for the development and commercialization of BL-8030, an oral treatment for hepatitis C virus.